COMPANY OVERVIEW

Advancing Carmeseal™ For The Treatment of Duchenne Muscular Dystrophy and Acute Heart Failure

---

LOCATION

---

THERAPEUTIC AREAS

Cardiovascular Disease

Rare Diseases

---

WEBSITE

https://phrixuspharmaceuticals.com/

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Sep 13, 2017

Phrixus Pharmaceuticals announces the first patient with Duchenne muscular dystrophy (DMD) to meet the 15-month mark on Carmeseal-MD™ (Poloxamer 188 NF)

For More Press Releases

---